105 related articles for article (PubMed ID: 26555339)
1. Progression of Alport Kidney Disease in Col4a3 Knock Out Mice Is Independent of Sex or Macrophage Depletion by Clodronate Treatment.
Kim M; Piaia A; Shenoy N; Kagan D; Gapp B; Kueng B; Weber D; Dietrich W; Ksiazek I
PLoS One; 2015; 10(11):e0141231. PubMed ID: 26555339
[TBL] [Abstract][Full Text] [Related]
2. Endothelial cell-specific collagen type IV-α
Funk SD; Bayer RH; Miner JH
Am J Physiol Renal Physiol; 2019 May; 316(5):F830-F837. PubMed ID: 30724107
[TBL] [Abstract][Full Text] [Related]
3. Hydroxypropyl-β-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis.
Mitrofanova A; Molina J; Varona Santos J; Guzman J; Morales XA; Ducasa GM; Bryn J; Sloan A; Volosenco I; Kim JJ; Ge M; Mallela SK; Kretzler M; Eddy S; Martini S; Wahl P; Pastori S; Mendez AJ; Burke GW; Merscher S; Fornoni A
Kidney Int; 2018 Dec; 94(6):1151-1159. PubMed ID: 30301568
[TBL] [Abstract][Full Text] [Related]
4. Coexisting presentation of two rare genetic variants of autosomal dominant polycystic kidney disease and Alport syndrome.
Venda J; Henriques A; Leal R; Alves R
BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38740443
[TBL] [Abstract][Full Text] [Related]
5. PDGF-D Is Dispensable for the Development and Progression of Murine Alport Syndrome.
Firat EAM; Buhl EM; Bouteldja N; Smeets B; Eriksson U; Boor P; Klinkhammer BM
Am J Pathol; 2024 May; 194(5):641-655. PubMed ID: 38309427
[TBL] [Abstract][Full Text] [Related]
6. Anti-microRNA-21 Therapy on Top of ACE Inhibition Delays Renal Failure in Alport Syndrome Mouse Models.
Rubel D; Boulanger J; Craciun F; Xu EY; Zhang Y; Phillips L; Callahan M; Weber W; Song W; Ngai N; Bukanov NO; Shi X; Hariri A; Husson H; Ibraghimov-Beskrovnaya O; Liu S; Gross O
Cells; 2022 Feb; 11(4):. PubMed ID: 35203245
[No Abstract] [Full Text] [Related]
7. The interface of genetics with pathology in alport nephritis.
Liapis H; Jain S
J Am Soc Nephrol; 2013 Dec; 24(12):1925-7. PubMed ID: 24071003
[No Abstract] [Full Text] [Related]
8. Depletion of macrophages with clodronate liposomes partially attenuates renal fibrosis on AKI-CKD transition.
Hu Z; Zhan J; Pei G; Zeng R
Ren Fail; 2023 Dec; 45(1):2149412. PubMed ID: 36636989
[TBL] [Abstract][Full Text] [Related]
9. Potential Renal Damage Biomarkers in Alport Syndrome-A Review of the Literature.
Gomes AM; Lopes D; Almeida C; Santos S; Malheiro J; Lousa I; Caldas Afonso A; Beirão I
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806283
[TBL] [Abstract][Full Text] [Related]
10.
Irion CI; Williams M; Capcha JC; Eisenberg T; Lambert G; Takeuchi LM; Seo G; Yousefi K; Kanashiro-Takeuchi R; Webster KA; Young KC; Hare JM; Shehadeh LA
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743114
[TBL] [Abstract][Full Text] [Related]
11. Macrophage Depletion Attenuates Acute Renal Damage after Exhaustive Exercise in Mice.
Mizokami T; Shimada M; Suzuki K
Int J Sports Med; 2022 Oct; 43(11):964-970. PubMed ID: 35426091
[TBL] [Abstract][Full Text] [Related]
12. Bardoxolone Methyl for Alport Syndrome: Opportunities and Challenges.
Quinlan C; Jayasinghe K
Clin J Am Soc Nephrol; 2022 Dec; 17(12):1713-1715. PubMed ID: 36411059
[No Abstract] [Full Text] [Related]
13. PPAR δ Agonism Ameliorates Renal Fibrosis in an Alport Syndrome Mouse Model.
Omachi K; O'Carroll C; Miner JH
Kidney360; 2023 Mar; 4(3):341-348. PubMed ID: 36657027
[TBL] [Abstract][Full Text] [Related]
14. Tauroursodeoxycholic acid ameliorates renal injury induced by COL4A3 mutation.
Yu S; Gu X; Zheng Q; Liu Y; Suhas T; Du W; Xie L; Fang Z; Zhao Y; Yang M; Xu J; Wang Y; Lin MH; Pan X; Miner JH; Jin Y; Xie J
Kidney Int; 2024 May; ():. PubMed ID: 38782199
[TBL] [Abstract][Full Text] [Related]
15. Molecular MR Imaging of Renal Fibrogenesis in Mice.
Chen YC; Waghorn PA; Rosales IA; Arora G; Erstad DJ; Rotile NJ; Jones CM; Ferreira DS; Wei L; Martinez RVP; Schlerman FJ; Wellen J; Fuchs BC; Colvin RB; Ay I; Caravan P
J Am Soc Nephrol; 2023 Jul; 34(7):1159-1165. PubMed ID: 37094382
[TBL] [Abstract][Full Text] [Related]
16. Targeting Fibrosis Pathways in Alport Syndrome-Is it Too Late?
Rheault MN
Kidney360; 2023 May; 4(5):580-581. PubMed ID: 37229728
[No Abstract] [Full Text] [Related]
17. Urinary Protein-Biomarkers Reliably Indicate Very Early Kidney Damage in Children With Alport Syndrome Independently of Albuminuria and Inflammation.
Rhode H; Lüse A; Tautkus B; Nabity M; John-Kroegel U; Weigel F; Dost A; Schitke J; Metzing O; Böckhaus J; Rubel D; Kiess W; Gross O
Kidney Int Rep; 2023 Dec; 8(12):2778-2793. PubMed ID: 38106579
[TBL] [Abstract][Full Text] [Related]
18. Alport Syndrome With Kidney Cysts Is Still Alport Syndrome.
Savige J; Mack H; Thomas R; Langsford D; Pianta T
Kidney Int Rep; 2022 Feb; 7(2):339-342. PubMed ID: 35155874
[No Abstract] [Full Text] [Related]
19. Efficacy of Dapagliflozin in Adult Autosomal Recessive Alport Syndrome.
Song ZR; Li Y; Zhou XJ; Zhang H
Kidney Int Rep; 2022 Sep; 7(9):2116-2117. PubMed ID: 36090488
[No Abstract] [Full Text] [Related]
20. An unusual macroscopic aspect of a kidney biopsy: a nephrology quiz.
Chauveau B; Burguet L; Merville P
J Nephrol; 2024 Mar; ():. PubMed ID: 38530602
[No Abstract] [Full Text] [Related]
[Next] [New Search]
